Development of recombinant rabies viruses vectors with Gaussia luciferase reporter based on Chinese vaccine strain CTN181

Virus Research

Volumn 160, Issue 1-2, 2011, Pages 82-88

  Du, Jialiang ^a   Tang, Qing ^a   Huang, Ying ^a   Rodney, Willoughby E ^b   Wang, Lihua ^a   Liang, Guodong ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Children's Hospital of Wisconsin   (United States)

Author keywords

CTN181; Gaussia luciferase; Rabies virus

Indexed keywords

ARGININE; GAUSSIA LUCIFERASE; GLUTAMINE; GLYCOPROTEIN; LUCIFERASE; RABIES VACCINE; RECOMBINANT RABIES VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES VIRUS; VIROGENESIS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CELL LINE; CRICETINAE; GENES, REPORTER; GENETIC ENGINEERING; GENETIC VECTORS; LUCIFERASES; RABIES VACCINES; RABIES VIRUS; RECOMBINATION, GENETIC; VIROLOGY;

RABIES VIRUS;

EID: 80052165777     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.05.018     Document Type: Article

References (51)

1. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., Marx P.A., McGettigan J.P. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 2009, 200(8):1251-1260.
2. Cenna J., Tan G.S., Papaneri A.B., Dietzschold B., Schnell M.J., McGettigan J.P. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 2008, 26(50):6405-6414.
3. Chen F., Xu Z., Lu J., Lv X., Mu W., Wang Y., Liu D., Liang C. Gaussia luciferase reporter assay for assessment of gene delivery systems in vivo. Chin. Med. Sci. J. 2010, 25(2):95-99.
4. Cheng M., Wu J., Meng S., Xu G. Protection of rabies vaccine prepared with CTN Strain against challenge with representative rabies street virus strains in China. Chin. J. Biologicals 2008, 21(9):786-787.
5. Conzelmann K.K., Schnell M.J. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J. Virol. 1994, 68(2):713-719.
6. d'Enfert C., Vecchiarelli A., Brown A.J. Bioluminescent fungi for real-time monitoring of fungal infections. Virulence 2010, 1(3):174-176.
7. Dietzschold B., Li J., Faber M., Schnell M. Concepts in the pathogenesis of rabies. Future Virol. 2008, 3(5):481-490.
8. Du J., Zhang Q., Tang Q., Li H., Tao X., Morimoto K., Nadin-Davis S.A., Liang G. Characterization of human rabies virus vaccine strain in China. Virus Res. 2008, 135(2):260-266.
9. Etessami R., Conzelmann K.K., Fadai-Ghotbi B., Natelson B., Tsiang H., Ceccaldi P.E. Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study. J. Gen. Virol. 2000, 81(Pt 9):2147-2153.
10. Faber M., Bette M., Preuss M.A.R., Pulmanausahakul R., Rehnelt J., Schnell M.J., Dietzschold B., Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J. Virol. 2005, 79(24):15405-15416.
11. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., Schnell M.J. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 2005, 86(Pt 5):1435-1440.
12. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., Chervoneva I., Montefiori D.C., Lackner A.A., Schnell M.J. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28(2):299-308.
13. Faul E.J., Wanjalla C.N., McGettigan J.P., Schnell M.J. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008, 382(2):226-238.
14. Feng B., Tomizawa K., Michiue H., Han X.J., Miyatake S., Matsui H. Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials 2010, 31(14):4139-4145.
15. Foley H.D., Otero M., Orenstein J.M., Pomerantz R.J., Schnell M.J. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J. Virol. 2002, 76(1):19-31.
16. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 2010, 84(6):2820-2831.
17. Griesenbach U., Vicente C.C., Roberts M.J., Meng C., Soussi S., Xenariou S., Tennant P., Baker A., Baker E., Gordon C., Vrettou C., McCormick D., Coles R., Green A.M., Lawton A.E., Sumner-Jones S.G., Cheng S.H., Scheule R.K., Hyde S.C., Gill D.R., Collie D.D., McLachlan G., Alton E.W. Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer. Biomaterials 2011, 32(10):2614-2624.
18. Hosokawa-Muto J., Ito N., Yamada K., Shimizu K., Sugiyama M., Minamoto N. Characterization of recombinant rabies virus carrying double glyeoprotein genes. Microbiol. Immunol. 2006, 50(3):187-196.
19. Huang Y., Tang Q., Nadin-Davis S.A., Zhang S., Hooper C.D., Ming P., Du J., Tao X., Hu R., Liang G. Development of a reverse genetics system for a human rabies virus vaccine strain employed in China. Virus Res. 2010, 149(1):28-35.
20. Inoue K., Shoji Y., Kurane I., Iijima T., Sakai T., Morimoto K. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 2003, 107(2):229-236.
21. Ito N., Takayama-Ito M., Yamada K., Hosokawa J., Sugiyama M., Minamoto N. Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol. Immunol. 2003, 47(8):613-617.
22. Ito N., Sugiyama M., Yamada K., Shimizu K., Takayama-Ito M., Hosokawa J., Minamoto N. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol. 2005, 49(11):971-979.
23. Ito N., Takayama M., Ymada K., Sugiyama M., Minamoto N. Rescue of rabies virus from cloned cDNA and identification of the pathogenicity-related gene: glycoprotein gene is associated with virulences for adult mice. J. Virol. 2001, 75:9121-9128.
24. Jackson A.C., Rossiter J.P. Apoptosis plays an important role in experimental rabies virus infection. J. Virol. 1997, 71(7):5603-5607.
25. Kuang Y., Lackay S.N., Zhao L., Fu Z.F. Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection. Virus Res. 2009, 144(1-2):18-26.
26. Liang H., Tan Y., Dun C., Guo X. A recombinant rabies virus expressing luciferase. Acta Virol. 2010, 54(4):269-274.
27. Liu L., Gong K., Ming P., Huang Y., Tang Q., Xu G., Yan J., Zhao N., Zhang X., Gong Y. Reconstruction and expression of the MRI-contrast protein, ferritin, with recombinant rabies vectors. Biotechnol. Lett. 2010, 32(6):743-748.
28. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., Schnell M.J. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 2003, 77(1):237-244.
29. McKenna P.M., McGettigan J.P., Pomerantz R.J., Dietzschold B., Schnell M.J. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr. HIV Res. 2003, 1(2):229-237.
30. McKenna P.M., Koser M.L., Carlson K.R., Montefiori D.C., Letvin N.L., Papaneri A.B., Pomerantz R.J., Dietzschold B., Silvera P., McGettigan J.P., Schnell M.J. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis. 2007, 195(7):980-988.
31. Mebatsion T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J. Virol. 2001, 75(23):11496-11502.
32. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(14):7310-7314.
33. Morimoto K., Foley H.D., McGettigan J.P., Schnell M.J., Dietzschold B. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. Neurovirol. 2000, 6(5):373-381.
34. Morimoto K., Shoji Y., Inoue S. Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity. Virus Res. 2005, 111(1):61-67.
35. Pulmanausahakul R., Faber M., Morimoto K., Spitsin S., Weihe E., Hooper D.C., Schnell M.J., Dietzschold B. Overexpression of cytochrome c by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J. Virol. 2001, 75(22):10800-10807.
36. Rasalingam P., Rossiter J.P., Jackson A.C. Recombinant rabies virus vaccine strain SAD-l16 inoculated intracerebrally in young mice produces a severe encephalitis with extensive neuronal apoptosis. Can. J. Vet. Res. 2005, 69(2):100-105.
37. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 1994, 13(18):4195-4203.
38. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., Schnell M.J. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 2002, 292(1):24-34.
39. Tannous B.A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protocol 2009, 4(4):582-591.
40. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 2005, 11(3):435-443.
41. Vos A., Neubert A., Aylan O., Schuster P., Pommerening E., Müller T., Chivatsi D.C. An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol. Infect. 1999, 123(1):165-175.
42. Wanjalla C.N., Faul E.J., Gomme E.A., Schnell M.J. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine 2010, 29(1):130-140.
43. We Y., Wang H., Wu H., Yang F., Tripp R.A., Hogan R.J., Fu Z.F. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J. Virol. 2010, (Epub ahead of print).
44. Wickersham I.R., Finke S., Conzelmann K.K., Callaway E.M. Retrograde neuronal tracing with a deletion mutant rabies virus. Nat. Methods 2007, 4(1):47-49.
45. Wickersham I.R., Sullivan H.A., Seung H.S. Production of glycoprotein-deleted rabies viruses for monosynaptic tracing and high-level gene expression in neurons. Nat. Protocol 2010, 5(3):595-606.
46. Wu X., Rupprecht C.E. Glycoprotein gene relocation in rabies virus. Virus Res. 2008, 131:95-99.
47. Yu Y.X. Development and status quo of domestic and abroad rabies vaccines. Shanghai J. Prev. Med. 2006, 18:216-218.
48. Zhang Y., Gao C., Wang Z., Zhao G., Sun Y., Li C., Wang S., Qin X. Study on a new rabies vaccine prepared from CTN strain virus propagated in primary hamster kidney cell culture. Prog. Microbiol. Immunol. 2002, 30(4):10-13.
49. Zhao L., Toriumi H., Kuang Y., Chen H., Fu Z.F. The roles of chemokines in rabies virus infection: over-expression may not always be beneficial. J. Virol. 2009, 83(22):11808-11818.
50. Zhao L., Toriumi H., Wang H.L., Kuang Y., Guo X.F., Morimoto K., Fu Z.F. Expression of MIP-1 (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. J. Virol. 2010, 84(18):9642-9648.
51. Zhu W., Zhou J., Qin K., Du N., Liu L., Yu Z., Zhu Y., Tian W., Wu X., Shu Y. A reporter system for assaying influenza virus RNP functionality based on secreted Gaussia luciferase activity. Virol. J. 2011, 8(1):29. 10.1186/1743-422X-8-29.